{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:15:33Z","timestamp":1791778533669,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2008,7,3]],"date-time":"2008-07-03T00:00:00Z","timestamp":1215043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,7,3]],"date-time":"2008-07-03T00:00:00Z","timestamp":1215043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1038\/leu.2008.174","type":"journal-article","created":{"date-parts":[[2008,7,3]],"date-time":"2008-07-03T10:03:13Z","timestamp":1215079393000},"page":"1925-1932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":182,"title":["Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma"],"prefix":"10.1038","volume":"22","author":[{"given":"I","family":"Breitkreutz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Vallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Hideshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Mitsiades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Okawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N C","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P G","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K C","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,7,3]]},"reference":[{"key":"BFleu2008174_CR1","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/nrc952","volume":"2","author":"T Hideshima","year":"2002","unstructured":"Hideshima T, Anderson KC . Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2: 927\u2013937.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2008174_CR2","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","volume":"108","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458\u20133464.","journal-title":"Blood"},{"key":"BFleu2008174_CR3","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123\u20132132.","journal-title":"N Engl J Med"},{"key":"BFleu2008174_CR4","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133\u20132142.","journal-title":"N Engl J Med"},{"key":"BFleu2008174_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","volume":"127","author":"S Jagannath","year":"2004","unstructured":"Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165\u2013172.","journal-title":"Br J Haematol"},{"key":"BFleu2008174_CR6","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487\u20132498.","journal-title":"N Engl J Med"},{"key":"BFleu2008174_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0037-1963(01)90020-4","volume":"38","author":"NS Callander","year":"2001","unstructured":"Callander NS, Roodman GD . Myeloma bone disease. Semin Hematol 2001; 38: 276\u2013285.","journal-title":"Semin Hematol"},{"key":"BFleu2008174_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"JR Berenson","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S et al., Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488\u2013493.","journal-title":"N Engl J Med"},{"key":"BFleu2008174_CR9","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","volume":"103","author":"JW Lee","year":"2004","unstructured":"Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004; 103: 2308\u20132315.","journal-title":"Blood"},{"key":"BFleu2008174_CR10","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483\u20132494.","journal-title":"N Engl J Med"},{"key":"BFleu2008174_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","volume":"131","author":"M Zangari","year":"2005","unstructured":"Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005; 131: 71\u201373.","journal-title":"Br J Haematol"},{"key":"BFleu2008174_CR12","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","volume":"135","author":"E Terpos","year":"2006","unstructured":"Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135: 688\u2013692.","journal-title":"Br J Haematol"},{"key":"BFleu2008174_CR13","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","volume":"21","author":"I von Metzler","year":"2007","unstructured":"von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007; 21: 2025\u20132234.","journal-title":"Leukemia"},{"key":"BFleu2008174_CR14","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1182\/blood-2005-08-3450","volume":"107","author":"G Anderson","year":"2006","unstructured":"Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006; 107: 3098\u20133105.","journal-title":"Blood"},{"key":"BFleu2008174_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0093-7754(01)90033-8","volume":"28","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC . Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001; 28: 607\u2013612.","journal-title":"Semin Oncol"},{"key":"BFleu2008174_CR16","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487\u20132498.","journal-title":"N Engl J Med"},{"key":"BFleu2008174_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1126\/science.7939685","volume":"266","author":"AE Grigoriadis","year":"1994","unstructured":"Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266: 443\u2013448.","journal-title":"Science"},{"key":"BFleu2008174_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S8756-3282(00)00445-2","volume":"28","author":"DJ Rieman","year":"2001","unstructured":"Rieman DJ, McClung HA, Dodds RA, Hwang SM, Holmes MW, James IE et al. Biosynthesis and processing of cathepsin K in cultured human osteoclasts. Bone 2001; 28: 282\u2013289.","journal-title":"Bone"},{"issue":"Part 14","key":"BFleu2008174_CR19","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1242\/jcs.115.14.2919","volume":"115","author":"R Faccio","year":"2002","unstructured":"Faccio R, Grano M, Colucci S, Villa A, Giannelli G, Quaranta V et al. Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. J Cell Sci 2002; 115 (Part 14): 2919\u20132929.","journal-title":"J Cell Sci"},{"key":"BFleu2008174_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S8756-3282(01)00657-3","volume":"30","author":"SE Lee","year":"2002","unstructured":"Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH et al. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 2002; 30: 71\u201377.","journal-title":"Bone"},{"key":"BFleu2008174_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/386081a0","volume":"386","author":"MM Tondravi","year":"1997","unstructured":"Tondravi MM, McKercher SR, Anderson K, Erdmann JM, Quiroz M, Maki R et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 1997; 386: 81\u201384.","journal-title":"Nature"},{"key":"BFleu2008174_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL . Osteoclast differentiation and activation. Nature 2003; 423: 337\u2013342.","journal-title":"Nature"},{"key":"BFleu2008174_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1126\/science.7939685","volume":"266","author":"AE Grigoriadis","year":"1994","unstructured":"Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266: 443\u2013448.","journal-title":"Science"},{"key":"BFleu2008174_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/360741a0","volume":"360","author":"ZQ Wang","year":"1992","unstructured":"Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF . Bone and haematopoietic defects in mice lacking c-fos. Nature 1992; 360: 741\u2013745.","journal-title":"Nature"},{"key":"BFleu2008174_CR25","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1534-5807(02)00369-6","volume":"3","author":"H Takayanagi","year":"2002","unstructured":"Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889\u2013901.","journal-title":"Dev Cell"},{"key":"BFleu2008174_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","volume":"102","author":"BO Oyajobi","year":"2003","unstructured":"Oyajobi BO, Franchin G, Williams PJ, Pulkrabek D, Gupta A, Munoz S et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003; 102: 311\u2013319.","journal-title":"Blood"},{"key":"BFleu2008174_CR27","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","volume":"97","author":"JH Han","year":"2001","unstructured":"Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD . Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001; 97: 3349\u20133353.","journal-title":"Blood"},{"key":"BFleu2008174_CR28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671","volume":"96","author":"SJ Choi","year":"2000","unstructured":"Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000; 96: 671\u2013675.","journal-title":"Blood"},{"key":"BFleu2008174_CR29","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","volume":"100","author":"M Abe","year":"2002","unstructured":"Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002; 100: 2195\u20132202.","journal-title":"Blood"},{"key":"BFleu2008174_CR30","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","volume":"101","author":"S Lentzsch","year":"2003","unstructured":"Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY . Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003; 101: 3568\u20133573.","journal-title":"Blood"},{"key":"BFleu2008174_CR31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1126\/science.285.5425.260","volume":"285","author":"PA Moore","year":"1999","unstructured":"Moore PA, Belvedere O, Orr A, Pieri K, La Fleur DW, Feng P et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260\u2013263.","journal-title":"Science"},{"key":"BFleu2008174_CR32","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1084\/jem.188.6.1185","volume":"188","author":"M Hahne","year":"1998","unstructured":"Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998; 188: 1185\u20131190.","journal-title":"J Exp Med"},{"key":"BFleu2008174_CR33","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","volume":"106","author":"J Moreaux","year":"2005","unstructured":"Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106: 1021\u20131030.","journal-title":"Blood"},{"key":"BFleu2008174_CR34","doi-asserted-by":"publisher","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","volume":"66","author":"YT Tai","year":"2006","unstructured":"Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006; 66: 6675\u20136682.","journal-title":"Cancer Res"},{"key":"BFleu2008174_CR35","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","volume":"103","author":"J Moreaux","year":"2004","unstructured":"Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148\u20133157.","journal-title":"Blood"},{"key":"BFleu2008174_CR36","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","volume":"106","author":"J Moreaux","year":"2005","unstructured":"Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106: 1021\u20131030.","journal-title":"Blood"},{"key":"BFleu2008174_CR37","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/sj.leu.2404228","volume":"20","author":"M Abe","year":"2006","unstructured":"Abe M, Kido S, Hiasa M, Nakano A, Oda A, Amou H et al. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 2006; 20: 1313\u20131315.","journal-title":"Leukemia"},{"key":"BFleu2008174_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/sj.leu.2405048","volume":"22","author":"S Yaccoby","year":"2008","unstructured":"Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B et al. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 2008; 22: 406\u2013413.","journal-title":"Leukemia"},{"key":"BFleu2008174_CR39","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1182\/blood-2002-01-0148","volume":"99","author":"O Sezer","year":"2002","unstructured":"Sezer O, Heider U, Jakob C, Zavrski I, Eucker J, Possinger K et al. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 2002; 99: 4646\u20134647.","journal-title":"Blood"},{"key":"BFleu2008174_CR40","first-page":"5438","volume":"63","author":"AN Farrugia","year":"2003","unstructured":"Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003; 63: 5438\u20135445.","journal-title":"Cancer Res"},{"key":"BFleu2008174_CR41","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1182\/blood-2002-09-2684","volume":"101","author":"O Sezer","year":"2003","unstructured":"Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC . RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003; 101: 2094\u20132098.","journal-title":"Blood"},{"key":"BFleu2008174_CR42","first-page":"287","volume":"63","author":"K Vanderkerken","year":"2003","unstructured":"Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003; 63: 287\u2013289.","journal-title":"Cancer Res"},{"key":"BFleu2008174_CR43","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"E Terpos","year":"2003","unstructured":"Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102: 1064\u20131069.","journal-title":"Blood"},{"key":"BFleu2008174_CR44","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1038\/sj.leu.2403890","volume":"19","author":"E Terpos","year":"2005","unstructured":"Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory\/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL\/osteoprotegerin ratio. Leukemia 2005; 19: 1969\u20131976.","journal-title":"Leukemia"}],"updated-by":[{"DOI":"10.1038\/leu.2008.216","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T00:00:00Z","timestamp":1224028800000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2008174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2008174","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2008174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:10:12Z","timestamp":1648725012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2008174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,3]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["BFleu2008174"],"URL":"https:\/\/doi.org\/10.1038\/leu.2008.174","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/leu.2008.216","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,3]]},"assertion":[{"value":"28 February 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}